Cyclophosphamide (CP), a widely used cytostatic, is metabolized by polymorphic drug metabolizing enzymes particularly cytochrome P450 (CYP) enzymes. Its side effects and clinical efficacy exhibit a broad interindividual variability, which might be due to differences in pharmacokinetics. CP-kinetics were determined in 60 patients using a global and a population pharmacokinetic model considering functionally relevant polymorphisms of CYP2B6, CYP2C9, CYP2C19, CYP3A5, and GSTA1. Moreover, metabolic ratios were calculated for selected CP metabolites, analyzed by 31 P-NMR-spectroscopy. Analysis of variance revealed that the CYP2C19*2 genotype influenced significantly pharmacokinetics of CP at doses p1000 mg/m 2 , whereas there was no evidence of an association of other genotypes to CP elimination or clearance. Mean (7SD) CP elimination constants k e (h À1 ) were 0.10970.025 in 44 CYP2C19*1/*1 subjects, 0.08870.018 in 13 CYP2C19*1/*2, and 0.07670.014 in three inactive CYP2C19*2/*2 carriers (P ¼ 0.009). At CP doses higher than 1000 mg/m 2 , a significantly increase of elimination was observed (P ¼ 0.001), possibly due to CYP induction. Further studies should link these findings with the clinical outcome.
INTRODUCTION
The cytostatic drug cyclophosphamide (CP), an N-lost derivative, is applied in mono-or polychemotherapy regimes for various indications such as malignant lymphomas, 1 acute and chronic lymphatic leukemia, 2 and solid tumors like breast cancer, 3 or for immuno-suppression. 4 CP treatment may result in partly severe side effects such as anemia, leukocytopenia and thrombocytopenia, gonadal toxicity 5 and even development of secondary tumors. 6 The acute and delayed type of cytostatic drug-induced nausea and vomiting are presumably a result of direct stimulation of the chemoreceptor trigger zone by various nitrogen mustard metabolites of CP. 7 Nausea and vomiting is seen in most patients who receive doses above 50 mg/kg body weight. 8, 9 Moreover, significant urotoxicity 10 is attributed to the direct toxic effect of the CP metabolite acrolein. 11 As activation and elimination of CP is mediated by various polymorphic drugmetabolizing enzymes (Figure 1 ), the question arises whether hereditary polymorphism could modulate the pharmacokinetics of CP. CP is believed to be predominantly activated to 4-hydroxyphosphamide by the polymorphic cytochrome P450 (CYP) enzymes CYP2C9 [12] [13] [14] and CYP2B6, [15] [16] [17] but also by CYP2C19 12, 13 and CYP3A. 14, 15 CYP3A4, CYP3A5 and CYP3A7 contribute to the heterogeneous expression of the human CYP3A family. 18 Individuals with at least one CYP3A5*1 allele copy (adenine in position 6986) produce high levels of full-length CYP3A5 mRNA and express active CYP3A5. 19 However, the majority (95%) of Caucasians have no active CYP3A5 due to an aberrantly spliced mRNA with a premature stop codon. 20 CP resistance is probably associated with an increased conjugation of aldophosphamide and phosphoramide mustard with glutathione through polymorphic glutathione Stransferase GSTA1. 21 Phosphoramide mustard is a product of a spontaneous disintegration of 4-hydroxyphosphamide, the primary CP metabolite. In a minor pathway, CP is dechloro-acetylated by CYP3A4/A5, generating the neurotoxic chloro-acetaldehyde. 14, 22, 23 Two other alternative metabolic pathways, which lead to inactive metabolites, are transformations of 4-hydroxyphosphamide into 4-oxocyclophosphamide and of aldophosphamide into carboxyphosphamide. The latter is generated by ALDH isoformes. [24] [25] [26] However, CP is also excreted unchanged into urine.
In the present study, the pharmacokinetics of CP were determined in 60 patients using a linear and a population pharmacokinetic model to analyze the effects of defined genotypes of the cytochrome P450 enzymes 2B6, 2C9, 2C19, and 3A5, as well as GSTA1 genotypes on the elimination constant and plasma clearance.
RESULTS
All subjects were genotyped and the genotype frequencies were in Hardy-Weinberg equilibrium. The allelic frequencies were as follows: CYP2B6*1: 59.2%, *2: 5.8%, *4: 4.2%, *5: 8.3%, *6: 16.7%, *7: 5.8%; CYP2C9*1: 77.5%, *2: 16.7%, *3: 5.8%; CYP2C19*1: 84.2%, CYP2C19*2: 15.8%; CYP3A5*1: 10%, *3: 90%, and GSTA1*A: 67.5%, *B: 32.5% (see Table 1 for genotype frequencies).
CP Plasma Elimination Rates
CP kinetics proved to be log-linear in two patients (being wild type for CYP2B6, CYP2C9, and CYP2C19) during 24 h (Figure 2 ). Accordingly, it was confirmed that blood Figure 1 Enzymatic bioactivation and inactivation of cyclophosphamide: CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 are involved in the initial metabolic activation to 4-hydroxyphosphamide being in tautomeric equilibrium with aldophosphamide. 4-Hydroxyphosphamide spontaneously disintegrates nonenzymatically into the alkylating metabolite phosphoramide mustard and the nephrotoxic acrolein. GSTA1 catalyzes conjugation of the aziridinium ion with glutathione. In a minor pathway, the dechloracetylation of CP, mediated by CYP3A4/A5, results in release of the neurotoxic agent chloroacetaldehyde. Two other alternative metabolic pathways, which lead to inactive metabolites, are transformations of 4-hydroxyphosphamide into 4-oxocyclophosphamide and of aldophosphamide into carboxyphosphamide, whereas carboxyphosphamide is formed by different isoformes of ALDH.
sampling at 4.5 h and at 17.9 h was within the log-linear phase in all other patients. In a first attempt, ANOVA in the whole group of 60 patients showed lack of significance between elimination constant k e , cytochrome P450 genotypes and creatinine clearance. However, separate analysis of each CYP enzyme revealed a decrease k e in carriers of deficient CYP2C19. Neither, genotypes of CYP2B6, CYP2C9, and CYP3A5, nor GSTA1 altered CP-pharmacokinetics in the 60 patients (Table 1) .
Strikingly, elimination was significantly increased when subjects received doses higher than 1000 mg/m 2 (k e ¼ 0.147 0.03 h À1 with doses 41000 mg/m 2 , k e ¼ 0.1070.03 h À1 with doses p1000 mg/m 2 ). The ANOVA of 49 subjects with CP doses p1000 mg/m 2 demonstrated a significant influence of the CYP2C19 genotype on CP elimination (P ¼ 0.009), whereas there was still no significant association between CP k e and the genotypes of the remaining metabolizing enzymes or creatinine clearance. Single analysis for CYP2C19 genotypes showed a gene-dose effect towards CP elimination (Kruskal-Wallis test P ¼ 0.008, Figure 3 ), whereas there was no significant relation of k e to the CYP2C19 genotype in patients receiving doses higher than 1000 mg/m 2 .
Population Pharmacokinetics of CP
The parameter values of the population pharmacokinetic model and their variances are shown in Table 2 . When parameterizing with rate constants and volumes, that is k e and V, the results of the two-stage analysis were confirmed.
The numerical values of k e were almost identical for all subjects. As in the linear model, the k e of CP was significantly smaller by a factor of 0.76 among patients receiving doses p1000 mg/m 2 as compared to patients receiving doses 41000 mg/m 2 . In addition, when doses p1000 mg/m 2 had been administered, the CYP2C19 genotype had a statistically significant influence on k e . Specifically, when one or two variant alleles were present, k e was significantly smaller than in noncarriers of variant alleles, however, without a gene-dose effect. Thus, the population model with CYP2C19 genotype as a covariate resulted in a value of k e smaller by a factor of 0.8 among patients noncarrying a variant CYP2C19 allele and receiving doses p1000 mg/m 2 as compared to patients receiving doses 41000 mg/m 2 , whereas patients carrying a variant CYP2C19 allele and receiving doses p1000 mg/m 2 had a k e smaller by a factor of 0.64 as compared to patients receiving doses 41000 mg/m 2 . In addition to these findings reproducing the results of two-stage analysis, the body surface area (BSA) was identified as a covariate to the volume of distribution V. Neither age, sex, nor any of the other genes than CYP2C19 had a significant influence on k e or V. A different result with respect to the influence of CYP2C19 genetics on CP pharmacokinetics was obtained when parameterizing with CP plasma clearance CL and V. In this case the effect of CYP2C19 variants on the elimination of CP could not be demonstrated as indicated by a nonsignificant improvement of fit when assigning CYP2C19 a covariate to the CP clearance from patients having received doses p1000 mg/ m 2 . In contrast, variance in CL was explained by the creatinine clearance and BSA was again a covariate on V. Interestingly, there was no difference in the clearance of CP with respect to the CP dose level.
Analysis of Metabolites in Urine
Urine metabolite analysis could be performed in only 10 patients. These patients received a mean CP dose of 747.376. regarding any genotype, and the sample did not include carriers of a deficient CYP2C19 genotype (Table 3) .
DISCUSSION
Carriers either heterozygous or homozygous for the deficient variant CYP2C19 allele showed lowered elimination constants, whereas there was no evidence of an association of the various genotypes of CYP2B6, CYP2C9, and CYP3A5 to pharmacokinetics of CP.
The linearity of CP kinetics itself is well established 27 and was proven in our study. Interestingly, we observed an increased elimination in the 11 subjects with CP doses higher than 1000 mg/m 2 (P ¼ 0.001). This was possibly caused by enzyme induction, particularly of CYP2B6. 28, 29 Reportedly, CYP2B6 induction is mediated via PXR/CAR binding motifs within the distal regulatory cluster. 30 On the other side, the CP clearance appeared to be dose-independent, therefore saturation of tissue binding could also contribute to this observation. Reanalysis of 49 subjects with CP doses p1000 mg/m 2 confirmed in a more pronounced way the association of the CYP2C19 genotype on CP elimination in the linear fit as well as in the population pharmacokinetics model, even when the creatinine clearance as indicator of kidney function was considered. However, parameterizing for CP clearance, the association was no longer significant. Owing to study design, only two blood samples were drawn from most patients, therefore the model of plasma clearance is much more uncertain than the crude CP elimination constant. As in the global analysis, there was still no association between elimination constants and the genotypes of the other metabolizing enzymes. A limitation of the model is the fact that we could not consider the influence of liver function due to incomplete patient's data. Moreover, comedication leading to possible interactions, was difficult to consider. For example, prednisolon, known to induce the CYP3A family, was administered in nearly all therapy regimens. Further, the conclusion drawn from metabolic ratios determined in urine in our study were limited, due to the small sample size and the lack of CYP2C19*2-carriers. Indicative, the two samples collected from patient carrying variant CYP2C9 alleles, had lower carboxyphosphamide/CP ratios than CYP2C9 wild types.
Previous studies demonstrated that several cytochrome P450 enzymes are able to catalyze CP 4-hydroxylation, however, results are partly conflicting. Some investigators identified CYP2B6 16, 17 as the major in vitro catalyst of 4-hydroxy CP, others characterized CYP2C9 as low K m hydroxylase, 12, 14 and CYP2C19 as high K m hydroxylase, 12, 13 but found also that CYP3A4/5 14 was an important enzyme for CP activation. The polymorphic GSTA1, however, contributes to the detoxification of reactive intermediates, therefore GSTA1 could be possibly associated with side effects of CP treatment.
The determination of well-characterized pharmacogenetic traits could help to understand the different enzymes involved in CP activation and detoxification. A lower 4-hydroxylase activity was shown in carriers of CYP2C9*2 or CYP2C9*3 12, 16 as well is an in vitro yeast expression system. 13 Moreover, CYP2C19.1-overexpressing cells had higher V max / K m ratios than CYP2C9.2 or 2C9.3, although in isolated human liver microsomes, the 4-hydroxycylophosphamide formation rate of CYP2C19*1/*2 was not significantly lower than that of CYP2C19*1/*1. In a study on the clinical outcome of pulse CP treatment of lupus erythematosusrelated nephritis, CYP2C19*2 carriers had a significantly lower risk of developing premature ovarian failure. 31 The role of CYP2B6 genotypes needs further clarification. CYP2B6*4 possibly exhibits an elevated activity, this was shown in an in vivo study on the bioavailability of the CYP2B6 substrate bupropion. 32 We observed a tendency in our study which corroborates this finding, although it did not reach statistical significance (P ¼ 0.089). In the study of Takada et al, 31 patients homozygous for CYP2B6*5 or CYP2C19*2 had a higher probability of reaching end-stage renal disease and exhibited higher serum creatinine levels.
Any genotype-related differences were not observed in patients getting a high-dose chemotherapy. Interestingly, a recent study on breast cancer patients under high-dose treatment demonstrated that patients, carrying active CYP3A5, displayed higher CP plasma levels and a slower apparent induction of CP metabolic activation. 33 On the other hand, they had a significant lower rate of survival in comparison to carriers of the inactive CYP3A5 variant. In our study high-dose patients (41000 mg CP/m 2 ) with the rare CYP3A5*1/*3 genotype had a slightly lower K e than those carrying CYP3A5*3/*3, without reaching statistical significance.
In conclusion, our results demonstrate that carriers of at least one CYP2C19*2 allele had lower CP elimination constants in the dose range below 1000 mg/m 2 , whereas there was lack of association with other genotypes. These results should be validated in prospective studies with larger patients groups and with respect to the clinical relevance. Most patients had been diagnosed for non-Hodgkin's lymphomas (n ¼ 37), Hodgkin's lymphoma (n ¼ 3), multiple myeloma (n ¼ 4), breast cancer (n ¼ 9) and other malignancies (n ¼ 3). For all patients, age, sex, height, weight, body surface area, and plasma creatinine concentrations were recorded. Patients received CP as a part of combined chemotherapy (CHOP, n ¼ 31, mean dose/body surface 7047171 mg/m 2 ; CHOEP, n ¼ 3, 7247171 mg/m 2 ; high-dose therapy n ¼ 6, 27317826 mg/m 2 ; other schemes n ¼ 16, 6757231 mg/m 2 ) or had been treated with CP for stem cell mobilization (n ¼ 4, 232771102 mg/m 2 ). The overall mean of the CP dose was 10087806 mg/m 2 . Venous blood samples (10-20 ml) were drawn at 4.5 and 17.9 h after the end of infusion. Urine was collected during the first and second 12 h following end of CP infusion. In two subjects, 24-h CPkinetics with seven blood samples at 60, 120, 240 (or 270), 490, 600, and 1320 (or 1380) min after end of the CP infusion were obtained. These patients received CP doses of 712.5 and 732.5 mg/m 2 , respectively.
DNA Extraction and Allelic Discrimination
Genomic DNA was isolated from EDTA blood using QIAamp s DNA Blood Mini Kit (QIAGEN, Hilden, Germany). CYP2C9 and CYP2C19 polymorphisms were determined by rapid cycle real-time PCR using FRET technology (LightCycler s , Roche Diagnostics, Mannheim, Germany). CYP2C9 genotyping for C430T (Arg144Cys; *2) and A1075C (Ile359-Leu; *3) was performed as described previously. 0 -GGG TTT CCG GGA AAT AAT CAA Tfluorescein-isothiocyanat (TIB Molbiol, Berlin, Germany). PCR conditions were 75 cycles of 2 s at 951C, 12 s at 551C, and 15 s at 721C (temperature slope 201C/s). Melting curve derivation revealed maxima of 531C for 681G and 441C for the variant 681A.
CYP2B6 was genotyped for the major alleles CYP2B6*2 (C64T), *3 (C777A), *4 (A785G), *5 (C1459T), *6 (G516T and A785G), and *7 (G516T, A785G, and C1459T) by PCR/RFLP using restriction enzymes HaeII, BsrI, StyI, and BglII, respectively, as described by Lang et al. 35 The inactive CYP3A5 allele *3 was determined according to 36 with Rsa I. Discrimination between the GSTA1 alleles *A and *B was achieved by using Ear I for PCR/RFLP analysis. 37 Analysis of CP Plasma Concentrations Plasma levels of CP (Sigma-Aldrich, Steinheim, Germany) were measured by high-performance liquid chromatography (HPLC). An aliquot of 100 ml plasma was spiked with 6 mg of the internal standard ifosfamide (Baxter Oncology GmbH, Frankfurt am Main, Germany) and extracted with 1 ml Bakerbond spet Octadecyl (C18) solid-phase extraction columns (Mallinckrodt Baker, Deventer, Netherlands). In all, 50 ml were injected into a HPLC system (Shimadzu, Berlin, Germany), using a 5 mm LiChroCART 4-4 RP-18 endcapped precolumn and a 5 mm LiChroCART 250-4 RP-18 endcapped column (Merck, Berlin, Germany). Temperature was maintained at 294 K by a CTO-10 ASVP column. The mobile phase consisted of acetonitrile/H 2 O (19 : 81, v : v) with a flow rate of 1 ml/min. All solvents and reagents were of HPLC grade and obtained from Mallinckrodt Baker (Deventer, Netherlands). CP and ifosfamide were detected using a UV-VIS detector set to 195 nm.
Retention times were 19.2 and 22.4 min for ifosfamide and CP, respectively. Plasma calibration curves were linear in the range from 5 to 200 mg/ml with a lower limit of quantification of 3 mg/ml.
Quality control samples with CP concentrations of 8, 80, and 180 mg/ml were included in each test series. The intraassay coefficients of variation were 7.3% (8 mg/ml), 1.3% (80 mg/ml), and 2.7% (180 mg/ml), and the inter assay coefficients of variation were 3.6, 7.7 and 3.5%, respectively.
Analysis of CP and Metabolites in Urine 1 H-decoupled 31 P NMR spectra were recorded with a Bruker Avance 600 spectrometer (Bruker, Karlsruhe, Germany) at a frequency of 242.9 MHz using a 5 mm diameter probehead at a temperature of 294 K. According to previously described methods, 38 we used the following acquisition and processing conditions: sweep width 41.163 parts per million (ppm), flip angle of about 251 (with a corresponding pulse width of 8 ms), acquisition time 1.64 s, relaxation delay 1.5 s, number of scans 16 K. Before Fourier transformation, data were multiplied by an exponential (line broadening 5 Hz) and zero filled to 32 K. Every measurement took 16 h. Urine samples of 2.7 ml were spiked with the internal standard methyltriphenylphosphonium bromide (Sigma-Aldrich, Steinheim, Germany). Then 0.3 ml of a buffer were added (7.9 g imidazole in 6 g deuteriumchloride (DCl) 35%, and 6 g deuteriumoxide (D 2 O); Sigma-Aldrich, Steinheim, Germany) and pH was adjusted to approximately 7 by addition of NaOH or HCl. The chemical shifts (d) were reported in ppm. The signals of carboxyphosphamide, CP, dechloroethyl-CP, and 4-oxo-CP were referenced relative to the internal standard (d CH 3 Ph 3 PBr ¼ 24.3 ppm) at 23.14, 18.53, 18.07, and 11.05 ppm, respectively (Figure 4) . Calibration curves were set up for CP and carboxyphosphamide (Baxter Oncology GmbH, Frankfurt am Main, Germany) and ranged from 35 to 5000 mmol/l for CP and from 50 to 3000 mmol/l for carboxyphosphamide.
Linearity was excellent (r values 0.9968 and 0.9997, respectively). Stability was recorded for 32 h and showed a slight decrease after 16 h which amounted to 8.8% for CP (2000 mmol/l) and to 9.5% for carboxyphosphamide (1500 mmo/l).
Statistical Analysis
In an initial two-stage pharmacokinetic analysis, the firstorder elimination rate constants, k e , were calculated using Origin 5.0 (OriginLab Corporation, Northampton, MA, USA) as the slope of the line between the first and the second data point of the log-transformed concentrations vs time plot. The values of k e were compared between CYP genotypes of phenotypes using nonparametric tests for independent samples (Mann-Whitney U-test or Kruskal-Wallis test, where applicable). The a-level was set at 0.05. Statistical analyses were performed using SPSS 11.0 (SPSS Inc., Chicago, IL, USA).
A population pharmacokinetic analysis was performed to further identify relations of covariates age, sex, body surface area, clearance of creatinine, and CYP genotypes to the pharmacokinetic parameters of CP. The disposition of CP was described by a one-compartment model with first-order elimination, both with parameterizations k e and V (volume of distribution) and again with clearance, CL, and V. The fits were performed using the NONMEM computer software (NONMEM V version 1.1, GloboMax LLC, Hanover, MD, USA) such that plasma concentrations were analyzed by nonlinear regression. Log-normally distributed inter-individual variances of CL and V were used: P i ¼ y i;TV Á e Z i , where P i is the value of the parameter of the individual, y i,TV is the typical value (TV) of this parameter in the population, and Z is a variable accounting for the interindividual variability, with mean zero and variance o 2 . It was first assessed whether a structural parameter of the pharmacokinetic model varied interindividually. This was carried out by fitting two models, a reduced model with Z being set to zero and a full model with Z being allowed to be estimated. If the full model resulted in a significantly better fit of the data, an interindividual variance of the respective structural pharmacokinetic parameter was demonstrated. Goodness-of-fit was assessed using the likelihood ratio test: NONMEM objective function being minus twice the logarithm of the likelihood was minimized to obtain the best estimation of the model parameters and their variances. A difference of the minimal value of the objective function between the reduced and the full model exceeding 3.841 was considered significant (P ¼ 0.05). After interindividual variances of the pharmacokinetic parameters had been established, it was checked whether a part of this variance could be explained by covariates, using again the likelihood ratio test to judge whether introduction of a covariate significantly improved the fit. For example, to assess the influence of age on k e , a full model was created with k e ¼ y 1 Á Age 61
y2
Áe Z , where 61 (years) was the median age in the study sample. By fixing y 2 at zero and by leaving it free to be estimated, a reduced and a full model were obtained and their fitting performance was compared by applying goodness-of-fit criteria as above. The residual error e was modeled using a proportional error model. Calculations were performed using 'first-order conditional estimation' and 'Z-e interaction'. 
